Race Not Reported In Over 50 Percent Of Randomized Clinical Trials For Cardiovascular Disease
Posted on: Wednesday, 14 October 2009, 11:15 CDT
A new study recently published online by the American Heart Journal shows that more than half of all randomized clinical trials, or RCTs, for cardiovascular disease are not reporting vital information about the study populations race or ethnicity. NYU School of Medicine researchers found that out of the 156 cardiovascular disease RCTs analyzed, only 35% of trials reported any information on race or ethnicity between 1970 and 2006. From 2000 to 2006, 46% of trials included that information.
"Over time, information on enrollment by race and ethnic group has improved but nevertheless, information on this important demographic of patient enrollment is far from ideal," said Jeffrey S. Berger, MD, MS, Director of Cardiovascular Thrombosis; Assistant Professor of Medicine and Surgery at The Leon H. Charney Division of Cardiology at NYU School of Medicine. "It is imperative that all studies provide basic information including race and ethnicity. Furthermore, we must have good representation of different ethnic and minority groups in RCTs to apply data appropriately."
According to study authors, diversity in RCTs must be increased because representation of minority ethnic groups remains too low. Study findings showed that only 15% of trials had sufficient diversity to even attempt efficient analysis of results by race. Researchers also cited that RCTs in the United States were more likely to report race than international trials with no U.S. participants. However, enrollment information on race in the U.S. was still less than one third of total trials. RCTs funded by industry, federal agency or a foundation all reported race with similar frequency.
"Our study should have important implications for future design and publication of randomized clinical trials," said Dr. Berger. "Race and ethnic demographics should be strongly encouraged in future study publications, along with the optimal approach of mandating the reporting of race and ethnic group in all RCTs including cardiovascular disease trials. This way we can successfully move forward, enhancing the translation of study results with better targeted therapies for the diverse patient populations we treat."
---
On the Net:
Related Articles
- American Heart Association Late-Breaking Clinical Trial Report: Study Finds no Significant Cardiovascular Differences Between More Aggressive or Restrictive Post-Operative Treatment of Anemia
- Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
- Cancer Center to Use Wellness Professionals(TM) Ximega(TM) Omega-3 Supplement in Clinical Trial to Study Efficacy in Patients With Depression and Pancreatic Cancer
- BrainStorm Cell Therapeutics Initiates Stem Cell Safety Study in Primates for Parkinson's Disease
- Case Study of American Healthways' Diabetes Disease Management Program
- Randomized, Controlled Trial of Dexamethasone in Neonatal Chronic Lung Disease: 13- to 17-Year Follow-Up Study: I. Neurologic, Psychological, and Educational Outcomes
- Randomized, Controlled Trial of Dexamethasone in Neonatal Chronic Lung Disease: 13- to 17-Year Follow-Up Study: II. Respiratory Status, Growth, and Blood Pressure
- U. Enlists Patients in Clinical Study Linked to Fatal Lung Disease
- Research And Markets: Study This Comprehensive Directory On Disease Management In 2004
- Studies Show Promise for Liver Disease
 |
 |
User Comments (0)
RSS Feeds